Isotype selection in antibody engineering

Nature Biotechnology

Volumn 25, Issue 12, 2007, Pages 1369-1372

  Salfeld, Jochen G ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABX IL 8; AMG 102; ANTIBODY; BERTILIMUMAB; CLENOLIXIMAB; CP 675 206; CP 751 871; CP 870893; CR 002; CRO 11 VCMMAE; DENOSUMAB; GEMTUZUMAB OZOGAMICIN; HGS 004; HUMV 833; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; INTERLEUKIN 13 ANTIBODY; KELIXIMAB; NATALIZUMAB; PANITUMUMAB; RECOMBINANT ANTIBODY; TGN 1412; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VECTIBIX; VISILIZUMAB; VOLOCIXIMAB;

AMINO ACID SUBSTITUTION; ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; CELL FUNCTION; CLINICAL TRIAL; DRUG TARGETING; HALF LIFE TIME; HUMAN; IMMUNOREGULATION; NATURAL SELECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MOTIF; REPRODUCIBILITY; REVIEW;

ANTIBODIES, MONOCLONAL; DRUG DESIGN; IMMUNOGLOBULIN G; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 36849001338     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1207-1369     Document Type: Review

References (23)

1. van der Neut Kolfschoten, M. et al. Science 317, 1554-1557 (2007).
2. Jefferis, R. Expert Opin. Biol. Ther. 7, 1401-1413 (2007).
3. Carter, P. Nat. Rev. Immunol. 6, 343-357 (2006).
4. Filpula, D. Biomol. Eng. 24, 201-215 (2007).
5. van der Zee, J.S. et al. J. Immunol. 137, 3566-3571 (1986).
6. Schuurman, J. et al. Immunology 97, 693-698 (1999).
7. Angal, S. Mol. Immunol. 30, 105-108 (1993).
8. Schuurman, J. et al. Mol. Immunol. 38, 1-8 (2001).
9. Aalberse, R.C. & Schuurman, J. Immunology 105, 9-19 (2002).
10. Forrer, K. et al. Anal. Biochem. 334, 81-88 (2004).
11. Taylor, F.R. et al. Anal. Biochem. 353, 204-208 (2006).
12. Yoo, E.M. et al. J. Immunol. 170, 3134-3138 (2003).
13. Lewis, M.J. Mol. Immunol. 45, 818-827 (2007).
14. Duncan, A. et al. Nature 332, 563-564 (1988).
15. Suitters, A.J. et al. J. Exp. Med. 179, 849-856 (1994).
16. Reddy, M.P. et al. J. Immunol. 164, 1925-1933 (2000).
17. Cole, M.S. et al. J. Immunol. 159, 3613-3621 (1997).
18. Beevenhouwer, D.O. Infect. Immun. 75, 1424-1435 (2007).
19. The workshop slides from Patrick G. Swann are available at www.aapspharmaceutica.com/meetings/files/57/swannho.pdf
20. Weinberg, W.C. et al. Cancer Metastasis Rev. 24, 569-584 (2005).
21. Dillon, T.M. et al. J. Chromatogr. A. 1053, 299-306 (2004).
22. Alyanakian, M.-A. et al. Vox Sang. 84, 188-192 (2003).
23. WHO Review of the notation for the allotypic and related markers of human immunoglobulins. Eur. J. Immunol. 6, 599-601 (1976).